Skip to search formSkip to main contentSkip to account menu

liblomycin

Known as: N(1)-(3-((3-(bis((3,4-bis(phenylmethoxy)phenyl)methyl)amino)propyl)methylamino)propyl)bleomycinamide, libromycin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
The relative ability of hyperthermia to potentiate the cytotoxicity of bleomycin A2 (BLM) and the lipophilic bleomycin analog… 
1991
1991
Liblomycin (NK313) is a novel derivative of bleomycin (BLM) and peplomycin (PEP). The cell kill kinetics of NK313 on rat ascites… 
1990
1990
Liblomycin (LBM), a novel bleomycin analogue, and bleomycin A2 (BLM A2) were compared with respect to their relative potential to… 
1990
1990
SummaryThe antitumor efficacy as well as hematologic and pulmonary toxicity of Liblomycin, a new lipophilic analog of bleomycin… 
Highly Cited
1989
Highly Cited
1989
A new model to predict antitumor activity of new analogues was developed, and the cross-resistance against cisplatin (CDDP) and… 
1989
1989
Three bleomycin (BLM)-resistant sublines were isolated from a human head and neck squamous cell carcinoma cell line (A-253… 
1989
1989
The objective of this study was to compare the relative in vitro cytotoxicity of bleomycin to that of two newer-generation… 
1988
1988
Liblomycin (NK313), a novel analog of bleomycin and peplomycin (PEP), produced acid soluble DNA, base propenals and nucleo bases… 
1987
1987
  • T. TakitaT. Ogino
  • 1987
  • Corpus ID: 12841991
Peplomycin, derivative of Bleomycin which was developed because of a lower pulmonary toxicity and broader anti-tumor spectrum in…